Synergistic integration of deep learning with protein docking in cardiovascular disease treatment strategies

Sana Yakoubi1,2,3

  • 1Faculty of Life and Environmental Sciences, University of Tsukuba, Ibaraki, Japan.

IUBMB Life
|May 15, 2024
PubMed

Insights

Tocopherol shows promise for cardiovascular disease (CVD) management. Molecular docking reveals significant interactions with key CVD proteins, supported by deep learning predictions for drug discovery.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Computational Biology

Background:

  • Cardiovascular diseases (CVD) represent a significant global health burden.
  • Tocopherol (Vitamin E) possesses antioxidant properties with potential therapeutic applications.
  • Understanding molecular interactions is crucial for developing novel CVD treatments.

Purpose of the Study:

  • To investigate the molecular interactions of tocopherol with key proteins implicated in CVD.
  • To assess the therapeutic potential of tocopherol-based nanoemulsions for CVD management.
  • To leverage deep learning models for predicting protein-ligand interactions.

Main Methods:

  • In silico molecular docking analysis of tocopherol against seven target proteins (1O8a, 4YAY, 4DLI, 1HW9, 2YCW, 1BO9, 1CX2).
  • Assessment of binding affinities, inhibitory potentials, and interaction patterns.
  • Utilized deep learning models (ESM1-b, ProtT5) for predicting protein-ligand interaction sites.

Main Results:

  • Tocopherol exhibited significant binding affinity with protein 4YAY (binding energy -6.39 kcal/mol, Ki 20.84 μM).
  • Favorable interactions were also observed with proteins 1HW9, 4DLI, 2YCW, and 1CX2.
  • Tocopherol adheres to pharmacokinetic rules for oral bioavailability and demonstrates safety (non-toxic, non-carcinogenic).

Conclusions:

  • Tocopherol shows considerable potential as a therapeutic agent for cardiovascular diseases.
  • Molecular docking and deep learning accurately predict tocopherol's interactions with CVD-related proteins.
  • This study supports tocopherol's development for CVD management and highlights AI's role in drug discovery.

Related Concept Videos

Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422